← back to search

Yulin Liu

Ministry of Education of the People's Republic of China · CN
Area of research
Cancer Research · Oncology
Research interest
Research interests include Peptidase Inhibition and Analysis, Cancer-related molecular mechanisms research, Radiomics and Machine Learning in Medical Imaging, and Signaling Pathways in Disease.
h-index
35
citations
4,811
works
280
NIH funding
primary concept
email

Recent publications

Discovery of W478, a novel SHMT2 inhibitor for the treatment of esophageal carcinoma
Bioorganic Chemistry 2025cited by 4position: middledoi
The therapeutic effect of Loranthus parasiticus lignan derivatives on collagen-induced arthritis in rats through the SHBG/NFκB pathway
Inflammopharmacology 2024cited by 4position: middledoi
Awareness of intratumoral bacteria and their potential application in cancer treatment
Discover Oncology 2023cited by 24position: middledoi
Automated assessment of necrosis tumor ratio in colorectal cancer using an artificial intelligence‐based digital pathology analysis
Medicine Advances 2023cited by 23position: middledoi
Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.
2023cited by 10position: contributordoi
Clinical practice guideline on bladder cancer (Part I)
UroPrecision 2023cited by 7position: middledoi
Clinical practice guideline on bladder cancer (Part II)
UroPrecision 2023cited by 3position: middledoi
Development and validation of a scoring system incorporating tumor growth pattern and perineural invasion for risk stratification in colorectal cancer
Journal of Investigative Medicine 2023cited by 3position: firstdoi
Additional file 8 of Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells
Figshare 2022cited by 0position: middledoi
Additional file 7 of Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells
Figshare 2022cited by 0position: middledoi
Additional file 6 of Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells
Figshare 2022cited by 0position: middledoi
Additional file 10 of Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells
Figshare 2022cited by 0position: middledoi
Additional file 9 of Single-cell RNA sequencing reveals the potential mechanism of heterogeneity of immunomodulatory properties of foreskin and umbilical cord mesenchymal stromal cells
Figshare 2022cited by 0position: middledoi
Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Frontiers in Oncology 2021cited by 64position: middledoi
Delivery of Cationic Platinum Prodrugs via Reduction Sensitive Polymer for Improved Chemotherapy
Small 2021cited by 31position: middledoi
LncRNA POU3F3 Contributes to Dacarbazine Resistance of Human Melanoma Through the MiR-650/MGMT Axis.
2021cited by 16position: contributordoi
Elevated LOXL2 expression by LINC01347/miR-328-5p axis contributes to 5-FU chemotherapy resistance of colorectal cancer.
2021cited by 12position: contributor
Ligustrazine reverts anthracycline chemotherapy resistance of human breast cancer by inhibiting JAK2/STAT3 signaling and decreasing fibrinogen gamma chain (FGG) expression.
2020cited by 15position: contributor
The Improvement of Immune Effect of Recombinant Human Beta-Defensin 2 on Hepatitis B Vaccine in Mice
Viral Immunology 2020cited by 8position: middledoi
Curcumin attenuates collagen-induced rat arthritis via anti-inflammatory and apoptotic effects
International Immunopharmacology 2019cited by 168position: middledoi
Down-regulation of testes-specific protease 50 induces apoptosis in human laryngocarcinoma HEp2 cells in a NF-κB-mediated pathway
Molecular Biology Reports 2014cited by 11position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Yufeng Liu · Yale Cancer Center5 papers (2022–2022)Xixi Yang · Harbin Medical University5 papers (2022–2022)Huifeng Zhong · Southern Medical University5 papers (2022–2022)Peng Huang · Sun Yat-sen University Cancer Center5 papers (2022–2022)Lian Ma · Shenzhen University5 papers (2022–2022) · 5 papers (2022–2022) · 5 papers (2022–2022)Maochuan Liao · Southern University of Science and Technology5 papers (2022–2022)Lichun Xie · Shenzhen University5 papers (2022–2022)Aijia Li · Northwestern Polytechnical University5 papers (2022–2022)Chuiqin Fan · Southern University of Science and Technology5 papers (2022–2022) · 5 papers (2022–2022)Manna Wang · Guangzhou Medical University5 papers (2022–2022)Yu Wang · Chongqing University4 papers (2022–2022)Yong Zhong · South China Agricultural University4 papers (2022–2022)Yue Wang · South China Agricultural University3 papers (2022–2022)Hongwu Wang · Tianjin University of Traditional Chinese Medicine3 papers (2022–2022)Yue Wang · Shanghai Medical College of Fudan University2 papers (2022–2022) · 2 papers (2022–2022)Ke Zhao · Fudan University2 papers (2023–2023)